Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia

Journal of Mental Health Policy and Economics

Volumn 6, Issue 2, 2003, Pages 67-75

  Loosbrock, Danielle L ^a   Zhao, Zhongyun ^a   Johnstone, Bryan M ^a,b   Morris, Lisa Stockwell ^c  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COST CONTROL; COVARIANCE; DATA BASE; FEMALE; HEALTH CARE COST; HUMAN; INSURANCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTPATIENT CARE; PRACTICE GUIDELINE; REGRESSION ANALYSIS; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; DRUG UTILIZATION; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HEALTH CARE COSTS; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MENTAL HEALTH SERVICES; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; SCHIZOPHRENIA; UNITED STATES;

EID: 0142154161     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50 (2): 85-94.
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51 (1): 8-19.
3. Rosenheck R, Cramer J, Allan E, Erdos J, Frisman LK, Xu W, Thomas J, Henderson W, Charney D. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Arch Gen Psychiatry 1999; 56 (6): 565-572.
4. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24 (1): 1-10.
5. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154 (4 Suppl): 1-63.
6. McEvoy JP, Scheifler PL, Frances A. Treatment of schizophrenia 1999. The expert consensus guideline series. J Clin Psychiatry 1999; 60 (11 Suppl): 3-80.
7. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154 (4): 466-474.
8. Tollefson GD, Beasley CM, Jr., Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154 (4): 457-465.
9. Beasley CM, Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124 (1-2): 159-167.
10. Beasley CM, Jr., Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14 (2): 111-123.
11. Moller HJ, Muller H, Borison RL, Schooler NR, Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995; 245 (1): 45-49.
12. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: An updated review of its use in the management of schizophrenia. Drugs 2001; 61 (1): 111-161.
13. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997; 58 (10 Suppl): 55-62.
14. Tran PV, Dellva MA, Tollefson GD, Beasley CM, Jr., Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58 (5): 205-211.
15. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997; 17 (3): 194-201.
16. Kampman O, Lehtinen K. Compliance in psychoses. Acta Psychiatr Scand 1999; 100 (3): 167-175.
17. Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, Henderson W, Charney D. Medication continuation and compliance: A comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000; 61 (5): 382-386.
18. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31 (1): 67-72.
19. Kopala LC. Spontaneous and drug-induced movement disorders in schizophrenia. Acta Psychiatr Scand (Suppl) 1996; 389: 12-17.
20. Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999; 187 (8): 496-502.
21. Cassano GB, Pini S, Saettoni M, Rucci P, Dell'Osso L. Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders. J Clin Psychiatry 1998; 59 (2): 60-68.
22. Miller NS, Fine J. Current epidemiology of comorbidity of psychiatric and addictive disorders. Psychiatr Clin North Am 1993; 16 (1): 1-10.
23. Brown MC, Akpaffiong MJ, Oji VU, Bethea C. Re-admissions to psychiatric hospital associated with non-compliance to neuroleptics. ASHP Midyear Clinical Meeting 1994; 29 (Dec): 368.
24. Weiden P, Glazer W. Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr Q 1997; 68 (4): 377-392.
25. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21 (3): 419-429.
26. Haywood TW, Kravitz HM, Grossman LS, Cavanaugh JL, Jr., Davis JM, Lewis DA. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995; 152 (6): 856-861.
27. Meltzer HY. Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin 1997; 14 (1): 1-20.
28. Canales PL, Olsen J, Miller AL, Crismon ML. Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs 1999; 12 (3): 179-188.
29. Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull 1998; 24 (1): 11-20.
30. McCombs JS, Nichol MB, Johnstone BM, Stimmel GL, Shi J, Smith RR. Use patterns conventional antipsychotic medications in medicaid patients with schizophrenia. J Clin Psychiatry 1999; 60 (0 Suppl): 5-11.
31. McCombs JS, Nichol MB, Johnstone BM, Stimmel GL, Shi J, Smith R. Antipsychotic drug use patterns and the cost of treating schizophrenia. Psychiatr Serv 2000; 51 (4): 525-527.
32. Lurie N, Popkin M, Dysken M, Moscovice I, Finch M. Accuracy of diagnoses of schizophrenia in Medicaid claims. Hosp Community Psychiatry 1992; 43 (1): 69-71.
33. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994; 331 (10): 650-655.
34. Revicki D, Brown R, Keller M, Gonzales J, Culpepper L, Hales R. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry 1997; 58: 47-58.
35. Clark W, Churchill D, Forwell L, MacDonald G, Foster S. To pay or not to pay? Can Med Assoc J 2000; 162: 195-198.
36. Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 1999; 37 (4 Suppl): AS81-86.
37. Wyatt RJ, Henter I, Leary MC, Taylor E. An economic evaluation of schizophrenia - 1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30 (5): 196-205.